Related references
Note: Only part of the references are listed.Genomic characterization of spleens in patients with myelofibrosis
Eran Zimran et al.
HAEMATOLOGICA (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomic characterization of spleens in patients with myelofibrosis
Eran Zimran et al.
HAEMATOLOGICA (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Quantification of the Mutant CALR Allelic Burden by Digital PCR Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation
Olivier Mansier et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
Mandy Brecqueville et al.
GENES CHROMOSOMES & CANCER (2012)
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells
Xiaoli Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition
Sonam Prakash et al.
MODERN PATHOLOGY (2012)
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
Elaine M. Boyd et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms
Sool Yeon Cho et al.
CANCER RESEARCH (2010)
How I treat symptomatic splenomegaly in patients with myelofibrosis
Ruben A. Mesa
BLOOD (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Does primary myelofibrosis involve a defective stem cell niche?: From concept to evidence
Jean-Jacques Lataillade et al.
BLOOD (2008)
Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis
Sergej Konoplev et al.
HUMAN PATHOLOGY (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders
Pin-Pen Hsieh et al.
MODERN PATHOLOGY (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders
DP O'Malley et al.
MODERN PATHOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia
RA Mesa et al.
BLOOD (2001)